跳至主要内容
临床试验/jRCT2080220736
jRCT2080220736未知3 期

Long-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 200 人开始时间: 待定
适应症

试验速览

阶段
3 期
入组人数
200
主要终点
ACR criteria

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Open-labelled, multicenter study

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Subjects who have completed the week 24 visit in the previous study
  • Treatment with methotrexate (MTX) 6-8mg/week (administered orally) has continued from the previous study.

排除标准

  • Functional Class 4 as defined by the ACR Classification of Functional Status in rheumatoid arthritis.
  • Cardiac or pulmonary function worsens markedly from the week 24 visit in the previous study to enrolment in this study.
  • Primary or secondary immunodeficiency, including HIV infection occurs from the week 24 visit in the previous study to enrolment in this study.
  • Hepatitis B, hepatitis C or tuberculosis infection occurs from the week 24 visit in the previous study to enrolment in this study.
  • Malignancy occurs from the week 24 visit in the previous study to enrolment in this study.

结局指标

主要结局

ACR criteria

the frequency of achievement of 20%, 50% and 70% in terms of the ACR criteria

DAS28

the frequency of achievement of 20%, 50% and 70% in terms of the DAS28

EULAR response rate

the frequency of achievement of 20%, 50% and 70% in terms of the EULAR response rate

HAQ-DI score

the frequency of achievement of 20%, 50% and 70% in terms of the HAQ-DI score

FACIT-Fatigue scale

the frequency of achievement of 20%, 50% and 70% in terms of the FACIT-Fatigue scale

persistence rate

the frequency of achievement of 20%, 50% and 70% in terms of the persistence rate

incidence of adverse events

Safety (incidence of adverse events)

Changes of endpoints

Changes of endpoints from the beginning of the treatment in the previous study

次要结局

未报告次要终点

研究者

相似试验